82 results about "Cytochrome" patented technology

The application discloses a kind of generation (4S) 4-hydroxyisophorone monooxygenase mutant and preparation method thereof, the monooxygenase is cytochrome P450 BM3 Monooxygenase from bacillus megaterium. The cytochrome P450 BM3 Monooxygenase mutant has high stereoselectivity and high reaction activity to catalyze isophorone hydroxylation, mutant R47L / Y51F / F81W / A191T / N239H / I259V / A276T / A328I / A330S / L353I / I401L / L437LL catalyzes isophorone to obtain (4S) 4-hydroxyisophorone diastereomeric excess rate can reach 95%, yield can reach 96%; the cytochrome P450 BM3 Monooxygenase mutant catalyzes isophorone synthesis (4S) 4-hydroxyisophorone process is simple, environmental protection, and industrialization prospect is good.

The invention provides a computer-implemented method and system for non-invasive and step-by-step prediction of cancer risks and a storage medium. The method comprises the following steps: (1) determining a cancer signal score based on the level of a biomarker in a blood sample of a subject; (2) comparing the cancer signal score with a preset threshold value, and determining a primary screening positive subject; (3) further performing cancer risk determination and cancer species prediction by adopting an NGS method on the basis of the primarily screened positive subjects; wherein the biomarker is selected from at least one of AFP (Alpha Fetal Protein), CA125, CA15-3, CA19-9, CA72-4, CEA (Carcino Embryonic Acid), CYFRA (Cytochrome Factor Receptor Amplification) 21-1, ProGRP (Proso-Growth Radical Polymerase Chain Reaction), SCCA (Sequence

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for modulating the activity of Cytochrome BD oxidase, or a mutant thereof. The disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of various diseases and disorders related to Cytochrome BD oxidase. Formula (I) and (II).

The present disclosure provides a P450 cytochrome enzyme for andrographolide synthesis and its application, belonging to the field of bioengineering. The present disclosure uses Saccharomyces cerevisiae CEN.PK2-1D as a host, and implements knockout of ROX1 and GAL80 genes on the genome, and integrative expression of GGPP synthase encoding gene and CPS diterpene synthase encoding gene at ROX1 site; and implements free expression of ApCPR and CYP71A8 and CYP71D10 both with truncated signal peptides, successfully constructing recombinant S. cerevisiae, and achieving de novo synthesis of 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid. Compared with the blank, a response value of a product peak reaches 1.9*106, and this strategy provides necessary reference for analyzing biosynthetic pathway of andrographolide and using metabolic engineering to synthesize andrographolide and related derivatives thereof.

The invention discloses ganoderic acid mass production and application based on cytochrome P450 enzyme CYP512W6, the cytochrome P450 enzyme CYP512W6 in ganoderma lucidum is converted into a corresponding saccharomyces cerevisiae strain for heterologous expression, and three kinds of ganoderic acid, namely TLTOA, 3 beta-TLTOA and DLDOA, are obtained after fermentation. The invention provides a new implementation mode for heterologous biosynthesis of ganoderic acid in saccharomyces cerevisiae.

This invention relates to a cytochrome P450 oxidase STO1, its encoding gene, and its applications. This invention is the first to clone and identify a cytochrome P450 oxidase gene, STO1, from potato responsible for catalyzing the synthesis of spirogelothoraxone, and to determine the nucleotide sequence and translated amino acid sequence of this gene. This invention provides expression vectors, recombinant microorganisms, or transgenic cell lines containing this gene. This invention constructs an engineered Saccharomyces cerevisiae strain for producing spirogelothoraxone, in which the strong promoter ERG9 is replaced by the weak promoter HXT1 in the strain's genome, and the STO1, AtCPR, tHMG1, and STS genes are integrated. This invention also provides a method for constructing this engineered strain and a method for producing spirogelothoraxone using this engineered strain, which can be used for the preparation of spirogelothoraxone.

Provided are: a method for measuring one or more biomarkers to simply and accurately diagnose diseases associated with changes in the activities of cytochrome P450 metabolic enzymes (hereinafter referred to as "P450s"); and a method for detecting the one or more biomarkers. The methods focus on luminescence-based detection of the enzymatic activities of P450s, and involves reacting one or more P450s present in a sample collected in a low- or non-invasive manner, such as serum or urine, with a precursor of a luminescent / light-emitting substrate, metabolizing a luminescent substrate converted from the precursor to generate luminescence, and measuring the generated luminescence. Since many molecular species of P450s are known, the activities of different molecular species of P450s can be measured for each disease on the basis of luminescence intensity, and the activity pattern of each P450 can be analyzed to detect one or more biomarkers.

The present invention addresses the problem of providing a cytochrome P450 protein by identifying a gene of a Cupressaceae plant involved in the biosynthesis of ferruginol and encoding the cytochrome P450 protein with said gene. The present invention also addresses the problem of providing a new method for producing ferruginol on the basis of said gene.　Provided is a cytochrome P450 protein of an isolated CYP720 family or an active fragment thereof, the protein having an activity of oxidizing the carbon at position 12 of an abietane-type diterpene. The cytochrome P450 protein or an active fragment thereof is derived from a plant selected from the group consisting of Cupressaceae, Taxaceae, Cephalotaxaceae, Podocarpaceae, and Araucariaceae.

The present invention relates to mutant enzymes with enhanced properties and methods of using such enzymes to oxidize organic compound substrates. More specifically, provided herein are mutations in cytochrome P450 enzymes that enhance their peroxygenase activity and / or alter product selectivity as compared to wild-type cytochrome P450 enzymes. Also provided are uses of such mutant cytochrome P450 enzymes, e.g., for biocatalytic oxidation of carbon-hydrogen bonds by a peroxygenase pathway, or for oxidation of organic compound substrates.

This method provides in situ quantification of the overall mitochondrial redox state, the redox state of individual cytochromes such as complex III and IV, and methods for treatment should the redox state be identified as hyperoxidized. Mitochondrial rescue from IRI-mediated injury can be achieved using methylene blue, which acts as an alternate electron donor to bypass complex III.

The invention provides a cytochrome P450 cholesterol side chain lyase mutant, recombinant saccharomyces cerevisiae for producing progesterone and application of the recombinant saccharomyces cerevisiae. The cytochrome P450 cholesterol side chain lyase mutant is obtained through ESM-2 language model screening, and the catalytic efficiency can be remarkably improved. The efficient recombinant saccharomyces cerevisiae is obtained by constructing the recombinant saccharomyces cerevisiae, optimizing the copy number of key enzymes, introducing an electron transfer system and overexpressing the key enzymes, the yield of progesterone is remarkably increased, and the recombinant saccharomyces cerevisiae is suitable for industrial production of progesterone and has important application value.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.

The present application provides a kind of cytochrome P450 monooxygenase gene and the protein coded by it, recombinant plasmid and application derived from ramie, the coding region sequence of the cytochrome P450 monooxygenase gene derived from ramie is as shown in SEQ ID NO:1, the amino acid sequence of the protein coded by it is as shown in SEQ ID NO:2.The present application takes ramie as research object, obtains ramie cytochrome P450 monooxygenase gene (BnMAX1) by three generations sequencing and gene annotation comparison.Longer coding sequence of the target gene is obtained by PacBio Sequel sequencing, which is simple, fast and easy to operate.The function of the gene is verified by cloning identification, bioinformatics, expression pattern and genetic transformation analysis, which shows that the gene has the effect of relieving plant cadmium toxicity.The acquisition and application of the gene provide basic theoretical support for molecular improvement of cadmium tolerance of ramie, and provide new technical means for how to improve the ecological restoration ability of ramie under heavy metal cadmium stress.

This invention relates to the field of pest control technology, and discloses a double-stranded RNA and its application in the control of citrus aphids. The double-stranded RNA comprises a double-stranded RNA consisting of the nucleotide sequence shown in SEQ ID NO:2 and its reverse complementary nucleotide sequence; the nucleic acid molecule encoding the double-stranded RNA is shown in SEQ ID NO:1 or SEQ ID NO:3. The double-stranded RNA provided by this invention can simultaneously target the chitin synthase gene, cytochrome P450 monooxygenase gene, and epidermal protein gene of the brown citrus aphid, and simultaneously silence the expression of these three key genes through an RNA interference mechanism, leading to inhibited growth and development or death of the brown citrus aphid. Therefore, the double-stranded RNA provided by this invention can efficiently and specifically control the brown citrus aphid; it can reduce the use of chemical pesticides, is green and environmentally friendly, and safe and harmless.

Described herein are steroid or steroid-like compounds including at least one isonitrile group and which inhibit the activity of a cytochrome P450 enzyme, as well as compositions including the compounds. Also included are methods of inhibiting activity of a cytochrome P450 in a subject having a steroid-responsive cancer, a Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound including at least one isonitrile group or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.

The present invention provides cytochrome bd oxidase inhibitors. The present invention provides the use of the cytochrome bd oxidase inhibitors as a medicament to treat a bacterial infection. The present invention also provides the use of the cytochrome bd oxidase inhibitors as a medicament to treat a bacterial infection with a QcrB inhibitor.

The present disclosure relates to relates to compounds that inhibit CYP3A4 selectively, pharmaceutical compositions, and methods of using the compounds and composition for treating a disease or disorder with a drug that is a P450 enzyme substrate. In addition, the disclosed compounds and compositions can be used for preventing P450 enzyme metabolism of a drug. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses application of fungal cytochrome P450 enzyme, and belongs to the technical field of biological enzyme catalysis. The fungal cytochrome P450 enzyme is derived from Gibberella fujikuroi, and the amino acid of the fungal cytochrome P450 enzyme is as shown in SEQ ID NO. 1 or has at least 80% similarity with the sequence as shown in SEQ ID NO. 1; the fungal cytochrome P450 enzyme at least can catalyze 7beta hydroxylation of five steroids L1, L2, L3, L4 and L5, and has excellent selectivity and high yield, and corresponding hydroxylation products can directly or indirectly generate ursodesoxycholic acid. The invention provides a good prospect for synthesizing ursodesoxycholic acid more environmentally and efficiently by using a biological enzyme method.

This invention discloses a herbicide-resistant cytochrome P450 gene, BjCYP71C2, its protein, plasmid, and their applications, belonging to the field of plant genetic engineering technology. The nucleotide sequence of this gene is SEQ ID NO:1 or has at least 80% identity with SEQ ID NO:1. This invention also discloses the protein polypeptide and plasmid encoded by the above gene. The purpose of this gene is to express it transgenic in plants, cultivating herbicide-resistant plants for selective weed control using herbicides.

The invention belongs to the technical field of enzyme composite materials and biological catalysis, and particularly relates to an immobilized enzyme catalyst based on a copper-based metal organic framework as well as a preparation method and application of the immobilized enzyme catalyst. Cytochrome c (Cyt c), squaric acid and copper ions are uniformly mixed through an in-situ co-precipitation method, in-situ embedding of Cyt c is achieved through hydrogen bonds and coordinate bonds generated in the Cu-MOF forming process, the Cyt c-coated Cu-MOF compound enzyme catalyst is prepared, a constructed Cu-MOF carrier is of a mesoporous structure, a stable protective microenvironment can be provided for Cyt c, enzyme leaching is effectively inhibited, and the catalyst has the advantages of being capable of being used for preparing the complex enzyme catalyst. The operation stability and the environmental tolerance are remarkably improved, and the catalyst shows efficient catalytic degradability in organic pollutants including phenolic compounds and dyes, and has wide application prospects in the fields of biological catalysis and the like. Moreover, the method is mild in condition, simple and convenient to operate, low in cost and easy for large-scale production.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

The present invention relates to a method of preparing a steroid comprising the step of converting a 7-deoxysteroid with a cytochrome P450 enzyme or a functional variant thereof in the presence of at least one redox partner system and a system for regenerating the redox partner system.

This invention discloses a method and its application for isolating mitochondria from mesenchymal stem cells (MSCs) to improve their yield, purity, and activity. Compared to existing methods for isolating MSCs, the method of this invention effectively improves the yield and purity of MSCs, increasing the number of mitochondria by 2.96 times. The method also better maintains the activity of MSC mitochondria, significantly increasing cytochrome C content and exhibiting superior activity in treating autoimmune hepatitis. Furthermore, the method is simple, requires minimal reagents, and has broad application prospects in the field of mitochondrial transplantation therapy.

Provided is an antibacterial application of a 3-phenyl-4H-benzopyran-4-one compound. Specifically, provided is use of a 3-phenyl-4H-benzopyran-4-one compound represented by formula I in the preparation of a product for inhibiting the proliferation of mycobacteria or treating diseases or conditions mediated by the proliferation of mycobacteria, and in the preparation of an in vitro reagent for inhibiting cytochrome bcc-aa3 oxidase and cytochrome bd oxidase of mycobacteria. Further disclosed are use of a 3-phenyl-4H-benzopyran-4-one compound represented by formula I' in the preparation of a product for improving the sensitivity of mycobacteria to cytochrome bcc-aa3 oxidase inhibitors, and a related composition. The compound is used for targeting a new target, and provides a new direction for the inhibition of mycobacterium tuberculosis and the treatment of related diseases.

The invention discloses a sensor for detecting cytochrome c and caspase in a single cell as well as a preparation method and application of the sensor. The sensor comprises a theta-type nanotube with two channels, wherein a cytochrome c aptamer and a caspase recognition peptide are respectively fixed on the two channels; one end of the theta-shaped nanotube is a tip, is provided with a theta-shaped nanopore and is used for puncturing into a single cell for sampling. Different detection molecules are respectively fixed in two channels of the theta-type nanotube, and synchronous, high-sensitivity and high-selectivity detection of two key apoptosis markers in a single cell is realized by utilizing the change of charge density on the inner wall of the channel when a target exists. The sensor has good reversibility, stability and reproducibility, can be used for monitoring dynamic changes of cyt c release and caspase-3 activation in a cell apoptosis process in real time, reveals spatial-temporal heterogeneity of an apoptosis mechanism, and provides a powerful tool for cell apoptosis research, disease diagnosis and treatment evaluation.

This invention relates to the design of specific primers for buffalo (Bubalus bubalis) cytochrome b (Cytb) gene for the detection of buffalo DNA using conventional PCR method. The primer sequence of buffalo species specific Cytb gene consists of forward sequence 5'- TTAGTACTATTCGCACCCGACCTC-3' and reverse 5'- TCGTTGTTTGGATGTATGTAGCAG-3'. This primer sequence has an amplicon size of 216 bp. The primers were used in a conventional PCR process operated under the following conditions, initiation stage of denaturation at 95ºC for 60 seconds, denaturation stage at 95ºC for 15 seconds, annealing stage at 63ºC for 15 seconds, elongation at 72ºC for 10 seconds cycle, final elongation at 72ºC for 60 seconds and at 35 cycles. This invention aims to amplify buffalo species specifically using conventional PCR methods so that it can detect the presence of buffalo DNA in processed products, especially for processed buffalo skin crackers.

The invention discloses a W-5 strain for improving pesticide tolerance of natural enemy insects and a culture method of the W-5 strain, the W-5 strain can well grow in a lowest-salt culture medium with lambda-lambda-cyhalothrin as a unique carbon source, the OD600 of a cultured bacteria solution is continuously increased, and the degradation rate of cyhalothrin pesticide reaches 98.24%. Furthermore, after the tenebrio molitor treated by the W-5 is fed to the hunting fuscipes, the activity of two types of key detoxifying enzymes, namely glutathione S-transferase and cytochrome P450, in the body of the hunting fuscipes can be remarkably improved. After the strain is continuously fed for one week, the W-5 is successfully colonized in intestinal tracts of the hpactor fuscipes, and the survival rate of the hpactor fuscipes under the stress of lambda-lambda-cyhalothrin is increased to 90.625%. Therefore, through double mechanisms of'direct microbial degradation 'and'host detoxification metabolism activation', the W-5 synergistically enhances the resistance of the Harpactor fuscipes to the lambda-lambda-cyhalothrin.

The present application belongs to the field of enzyme catalysis and bioengineering technology, and relates to a cytochrome P450 enzyme CYP153C3 and application thereof. The amino acid sequence of the enzyme is shown in SEQ ID NO. 1 of the sequence listing. The nucleotide sequence of the DNA molecule encoding the enzyme is shown in SEQ ID NO. 2 of the sequence listing. The cytochrome P450 enzyme CYP153C3 provided by the present application has catalytic activity on C8-C14 chain length saturated fatty acids, various unsaturated fatty acids and short-chain alkanes (octane, decane); meanwhile, the enzyme shows excellent ω-1 hydroxylation capacity on saturated fatty acids, unsaturated fatty acids and alkane substrates, has high regioselectivity, and can be used for green bio-manufacturing of high-value hydroxyl fatty acids and hydroxyl alkane compounds.

This invention relates to compounds of formula (IA), as well as their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation. The compounds disclosed herein can be used to treat diseases in which P-glycoprotein and / or cytochrome P450 (e.g., CYP3A4) are regulated (e.g., cancers that have developed multidrug resistance).